Muharrem İnce addresses a Republican People's Party meeting on May 4, 2018, in Ankara after being named the party's candidate to challenge President Erdoğan. Photo: Adem Altan/AFP via Getty Images

Turkey is slated to hold presidential and parliamentary elections on June 24. The current leadership has moved the vote forward by 16 months in the hopes of avoiding fallout from a badly deteriorating economy.

Why it matters: For Erdoğan, the combined elections are a matter of political survival after more than 15 years in power. For the opposition, they represent the first serious opportunity to send the incumbent president into retirement. For the citizens of Turkey, this boils down to a choice between a one-man-rule system with no checks and balances and a possible return to a more liberal and parliamentary system of governance.

Turkey’s dual elections on Sunday are deeply flawed:

  • The country’s ongoing state of emergency favors the current leadership.
  • The new election law is less fraud-proof.
  • On-air reporting is massively unfair, to the benefit of the incumbent president.
  • Kurdish presidential candidate Selahattin Demirtaş — who is running his campaign from jail — has been threatened with capital punishment by President Erdoğan himself.

The possible outcomes:

  1. An Erdoğan victory would mean more Turkish hostility toward Western powers. The U.S. would face a host of grievances, including the F35 delivery schedule, the use of the İncirlik Air Base and support to Syrian Kurds. Turkey, meanwhile, would try to reap maximum concessions from the EU — on trade, visa-free travel to Europe and support for Syrian refugees — while eschewing alignment with EU governance and economic standards. More importantly, should Erdoğan emerge electorally victorious but politically weaker with a narrow electoral margin — a real possibility — tensions with the West would put him at greater risk of Russian manipulation against NATO.
  2. A victory for the strongest anti-Erdoğan contender, Muharrem İnce, backed by a united parliamentary majority, would lead to a more amicable relationship with the West, especially if Turkish politics returned to a rule-based system. But to earn credibility, this new leadership would have to quickly take a stand on restoring a strong relationship with NATO and relaunching peace talks with Turkey’s Kurds. These are no small endeavors.

The big picture: Most polls predict that Erdoğan will carry the presidency. In that event, liberties and tolerance in Turkey's diverse society would fall even further, followed by Turkey’s alliance with the West.

Marc Pierini is a former EU ambassador to Turkey and a visiting scholar at Carnegie Europe.

Go deeper

Updated 19 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Politics: Chris Christie: Wear a mask "or you may regret it — as I did" — Senate Democrats block vote on McConnell's targeted relief bill.
  2. Business: New state unemployment filings fall.
  3. Economy: Why the stimulus delay isn't a crisis (yet).
  4. Health: FDA approves Gilead's remdesivir as a coronavirus treatment How the pandemic might endMany U.S. deaths were avoidable.
  5. Education: Boston and Chicago send students back home for online learning.
  6. World: Spain and France exceed 1 million cases.

FBI: Russian hacking group stole data after targeting local governments

FBI Headquarters. Photo: Mark Wilson/Getty Images

Energetic Bear, a Russian state-sponsored hacking group, has stolen data from two servers after targeting state and federal government networks in the U.S. since at least September, the FBI and Cybersecurity and Infrastructure Security Agency said on Thursday.

Driving the news: Director of National Intelligence John Ratcliffe announced Wednesday that Iran and Russia had obtained voter registration information that could be used to undermine confidence in the U.S. election system.

FDA approves Gilead's remdesivir as a coronavirus treatment

A production line of Remdesivir. Photo: Fadel Dawood/picture alliance via Getty Images

Gilead Sciences on Thursday received approval from the Food and Drug Administration for remdesivir, an antiviral treatment that has shown modest results against treating COVID-19.

Why it matters: It's the first and only fully FDA-approved drug in the U.S. for treating the coronavirus.